EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY 4.0

The impact of telemonitoring on correct drug use, complications and quality of life among patients with multiple myeloma (ITUMM): A study protocol for an open-label, parallel-group, randomized controlled trial

Job F H Eijsink iD, Paul A F Geerts, Karin Kamminga, Mireille A Edens, Cornelis Boersma, Maarten J Postma, Jan Gerard Maring, Peter G J Ter Horst

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0307177 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Job F H Eijsink und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Isala, Zwolle, The Netherlands. Hauptthemen laut MEDLINE: Multiple Myeloma, Quality of Life, Telemedicine. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen Nederland, isala klinieken.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Multiple myeloma (MM) is the second most common hematologic malignancy. MM is associated with significant morbidity due to its end-organ destruction and is a disease of the older population. Although survival rates for MM have improved over the last decade, due to an increase in treatment options, the disease remains incurable. Expensive (oral) agents are widely used in MM patients; however, tools for supporting patients in complex treatment regimens are scarce. To investigate if a tool will support MM patients and healthcare professionals, the MM e-coach was developed and tested. The aim of this study is to study the impact of telemonitoring on adherence, complications and quality of life in patients with MM (ITUMM study).

Methods

A two-arm open-label parallel-group randomized controlled trial will be conducted between March 2021 and June 2024 to compare the telemonitoring (MM e-coach) with standard MM care. This study aimed to recruit 150 patients with recently diagnosed multiple myeloma (RDMM), starting first or second line of treatment. Blinded primary outcome is adherence by pill count after start of treatment at 1–3 months. Secondary outcomes are patient reported outcomes: GFI, EQ-5D-5L, EORTC-QLQ-C30, SDM-Q-9, MARS-5, single item questions, PREMs, adverse events, OS and PFS. Patient reported outcomes were developed and integrated in the e-coach MM to regularly measure digitized outcomes of MM patients from time of RDMM until 12 months post-diagnosis. Online measurements will be performed at baseline (0), 3, 6, 9 and 12 months. Ethics and dissemination Ethics approval has been granted by the Ethics Committee of the Isala klinieken in The Netherlands (No. 201111) at 25 February 2021. Study results will be disseminated to the relevant healthcare communities by publication in peer-reviewed journals, and at scientific and clinical conferences. Study registration number ClinicalTrials.gov number: NCT05964270 and ABR number: NL75771.075.20.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaQuality of LifeTelemedicineFemaleHumansMaleMedication AdherenceRandomized Controlled Trials as Topic

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Isala, Zwolle, The Netherlands.
  • Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Internal Medicine, Isala, Zwolle, The Netherlands.
  • Department of Innovation and Science, Isala, Zwolle, The Netherlands.
  • Department of Management Sciences, Open University, Heerlen, The Netherlands.
  • Department of Economics, Econometrics & Finance, Faculty of Economics, University of Groningen, Groningen, The Netherlands.

ORCID-Profile: Job F H Eijsink

Förderung

  • Amgen Nederland
  • isala klinieken

Zitieren

APA

Eijsink, J. F. H., Geerts, P. A. F., Kamminga, K., Edens, M. A., Boersma, C., Postma, M. J., Maring, J. G., & Ter Horst, P. G. J. (2024). The impact of telemonitoring on correct drug use, complications and quality of life among patients with multiple myeloma (ITUMM): A study protocol for an open-label, parallel-group, randomized controlled trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0307177

Vancouver

Eijsink JFH, Geerts PAF, Kamminga K, Edens MA, Boersma C, Postma MJ, et al. The impact of telemonitoring on correct drug use, complications and quality of life among patients with multiple myeloma (ITUMM): A study protocol for an open-label, parallel-group, randomized controlled trial. PLOS ONE. 2024. doi:10.1371/journal.pone.0307177

BibTeX
@article{Eijsink2024,
  author = {Eijsink, Job F H and Geerts, Paul A F and Kamminga, Karin and Edens, Mireille A and Boersma, Cornelis and Postma, Maarten J and Maring, Jan Gerard and Ter Horst, Peter G J},
  title = {The impact of telemonitoring on correct drug use, complications and quality of life among patients with multiple myeloma (ITUMM): A study protocol for an open-label, parallel-group, randomized controlled trial},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0307177}
}
Kostenlos starten →